lundi 4 mai 2015

Onco Actu du 4 mai 2015

1.1 Biologie - Gènes

Our milestones: the discovery of the NRAS signalling gene [Cancer Research UK]

3. Prévention

Diet swap study highlights bowel effects of Western-style diet [NHS Choices]

3.1 Tabac

As youth vaping rises, teens cite the allure of tricks [Reuters]

3.5 Prévention - UV

Most Britons unaware of skin cancer signs - survey [BBC News]

Too many Britons are risking skin cancer by getting sunburned, says study [The Guardian]

4. Dépistage, diagnostic et pronostic

People’s views on screening differ. Perhaps their actions should, too. [AcademyHealth Blog]

Thank you for sharing [Nature News & Comment]

New test can predict cancer up to 13 years before disease develops [The Telegraph]

4.1 Dép., diag. & prono. - Prostate

Genomic Health Announces Publication of Oncotype DX® Prostate Cancer Test Decision Impact Study in Urology Practice, Supporting Wider Adoption and Reimbursement [Genomic Health]

4.7 Dép., diag. & prono. - Col de l'utérus

The Great Success And Enduring Dilemma Of Cervical Cancer Screening [NPR]

Experts clarify best intervals, ages for cervical cancer screening [Reuters]

5. Traitements

Anchor Trial Launch [National Cancer Institute]

New prostate cancer treatment has promising results in mice [NHS Choices]

Researchers prime immune system’s T cells with foreign antibodies to target cancer cell [Scope Blog]

Rociletinib shows promising activity against treatment-resistant EGFR-mutated lung cancer [Massachusetts General Hospital]

Personalized medicine: Time for one-person trials [Nature News & Comment]

New targeted drug promising treatment option in resistant EGFR-positive lung cancers [Dana-Farber Cancer Institute]

Prostate cancer could be 'wiped out' by new treatment [The Telegraph]

5.2 Pharma

Pharmas, Others Bet $33M More on Aileron’s P53 Peptide Drug [Xconomy]

Mirna rallies major players for $42M round, hits the gas in immuno-oncology [FierceBiotech]

Consumer DNA firms get serious about drug development [Nature News & Comment]

Celgene sales highlight Revlimid dependence ahead of patent ruling [Reuters]

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma [BMS]

Blueprint Medicines Bags $147M in Upsized IPO [Xconomy]

5.3 Traitements - FDA, EMA,...

EMA in 2014: A Landmark Year for Approvals, With Eyes on the Future [RAPS]

Progress in science, medicines, health [EMA]

Speedy Drug Approvals Have Become the Rule, Not the Exception [NY Times]

5.3.4 Traitements - AMM (FDA, EMA)

Amgen To Discuss Details Of The Biologics License Application For Talimogene Laherparepvec For Patients With Metastatic Melanoma [Amgen]

FDA panel gives a thumbs up to Amgen's T-Vec for melanoma [FierceBiotech]

FDA panel recommends approval for Amgen's skin cancer immunotherapy [Reuters]

5.5 ASCO

ASCO Highlights Capabilities to Electronically Share Clinical Information and Provide Coordinated Cancer Care at 2015 Annual Meeting [ASCO]

Cabozantinib and Cobimetinib to Be Featured in Fourteen Presentations at 2015 ASCO Annual Meeting [Exelixis]

6. Lutte contre les cancers

Looking at cancer as a chronic illness [Scope Blog]

Advice on being active should be routine in bowel cancer care [Cancer Research UK]

6.1 Observation

Worse survival after lung cancer surgery for residents of poor neighborhoods [Reuters]

6.10 Politiques

Regulatory Explainer: The (Updated) 21st Century Cures Act [RAPS]

FDA could approve drugs for new uses on less data: draft law [Reuters]

6.7 DMP, Big Data & applis

How Accurate Is US Patient Outcome Health Data? [Science 2.0]

Can Apple And IBM Change Health Care? Five Big Questions [Forbes]

6.9 Controverses

Statistics: P values are just the tip of the iceberg [Nature News & Comment]